Targeting the arginine metabolic brake enhances immunotherapy for leukaemia

Therapeutic approaches which aim to target Acute Myeloid Leukaemia through enhancement of patients’ immune responses have demonstrated limited efficacy to date, despite encouraging preclinical data. Examination of AML patients treated with azacitidine (AZA) and vorinostat (VOR) in a Phase II trial,...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Int J Cancer
Main Authors: Mussai, Francis, Wheat, Rachel, Sarrou, Evgenia, Booth, Sarah, Stavrou, Victoria, Fultang, Livingstone, Perry, Tracey, Kearns, Pamela, Cheng, Paul, Keeshan, Karen, Craddock, Charles, De Santo, Carmela
Format: Artigo
Jezik:Inglês
Izdano: John Wiley & Sons, Inc. 2019
Teme:
Tumor Immunology and Microenvironment
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6767531/
https://ncbi.nlm.nih.gov/pubmed/30485425
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.32028
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki